Topical amphotericin B for cutaneous leishmaniasis [8]

Archives of Dermatology

Volumn 135, Issue 7, 1999, Pages 856-857

  Vardy, Daniel ^a   Barenholz, Yechezkel ^a   Cohen, Rivka ^a   Zvulunov, Alex ^a   Biton, Amnon ^a   Klaus, Sidney ^a   Frankenburg, Shoshana ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETTER; PRIORITY JOURNAL; SKIN LEISHMANIASIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIASIS, CUTANEOUS; PROSPECTIVE STUDIES;

EID: 0032779840     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.135.7.856     Document Type: Letter

References (3)

1. Giri OP. Amphotericin B therapy in kala-azar. J Indian Med Assoc. 1993;91: 91-93.
2. Frankenburg S, Glick D, Klaus S, Barenholz Y. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B. Antimicrob Agents Chemother. 1998;42:3092-3096.
3. Klaus S, Axelrod O, Jonas F, Frankenburg S. Changing patterns of cutaneous leishmaniasis in Israel. Trans R Soc Trop Med Hyg. 1994;88:649-650.